ロード中...
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
BACKGROUND: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4423590/ https://ncbi.nlm.nih.gov/pubmed/25925749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1293-y |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|